Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Aortic Stenosis with Normal Flow Low Gradient: Should We Intervene or Wait?

Symptomatic patients with <1 cm² aortic valve area will benefit from an intervention regardless parameters such as flow and gradient, even if these are normal (or at least not severe).

Masa miocárdica fraccional para evaluar la severidad de la estenosisA valve replacement will be indicated without question (either surgical or percutaneous) in patients with >40 mHg mean gradient or low gradient justified by low flow. Much has been said and written about these cases and much will still be written. However, little has been published about patients with normal flow and low gradient.

 

Should we trust aortic valve area blindly when indicating an intervention such as a valve replacement?


Read also: Ten Commandments of the European Hypertension Guidelines: Several “Sins Allowed” Compared with American Guidelines.


Many specialists might question the severity of stenosis in these patients, especially when symptoms can be explained by other causes such as pulmonary or coronary causes.

 

This study included symptomatic patients with ≤ 1 cm² valve area, <40 mmHg mean gradient and > 35 ml/m² stroke volume index.

 

During the study period,1358 patients were assessed, and 303 (34%) met inclusion criteria.


Read also: TAVR Post-dilation Is Safe.


After a mean follow up of nearly 2 years, 60 patients (20%) died, with a global rate of 28%, 10% and 12% in the conservative treatment branch, TAVR and surgery respectively (p<0.001).

 

After adjusting for multiple variables, TAVR was associated with survival improvement vs. the conservative treatment (HR: 0.49; CI 95%:0.26 to 0.93; p=0.03), with no significant differences between surgery and TAVR. What made the difference was the intervention, regardless the type.

 

Conclusion

Symptomatic patients with <1 cm² valve area will benefit from intervention in terms of survival regardless low gradient and normal flow. The type of intervention had no impact on outcomes.

 

Original title: Intervention Versus Observation in Symptomatic Patients with Normal Flow-Low Gradient Severe Aortic Stenosis.

Reference: Oren Zusman et al. J Am Coll Cardiol Img 2018. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Left Atrial Appendage Closure: Implantation Depth Could Determine Thrombosis Risk

Left atrial appendage closure (LAAC) has undergone significant advances over the past two decades. This progress has been driven by the development of new...

Influence of cusp-overlap and three-cusp coplanar techniques on new-onset conduction disturbances after TAVI

New-onset conduction disturbances remain one of the most frequent complications after transcatheter aortic valve implantation (TAVI), being associated with worse long-term clinical outcomes. Among...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...